[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Miederer M, McDevitt MR, Borchardt P, Bergman I, Kramer K, Cheung NK, Scheinberg DA: Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2. Clin Cancer Res; 2004 Oct 15;10(20):6985-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2.
  • Labeling of specific antibodies with bifunctional chelated Actinium-225 ((225)Ac; an alpha generator) allows the formation of new, highly potent and selective alpha-emitting anticancer drugs.
  • The (225)Ac-1,4,7,10-tetra-azacylododecane (DOTA)-3F8 construct was evaluated for radiochemical purity and sterility, immunoreactivity, cytotoxicity in vitro, induction of apoptosis on GD2-positive cells, as well as for pharmacological biodistribution and metabolism of the (225)Ac generator and its daughters in a nude mouse xenograft model of neuroblastoma.
  • The (225)Ac-3F8 showed an IC(50) of 3 Bq/ml (80 pCi/ml) on the neuroblastoma cell line, NMB7, in vitro.
  • Biodistribution in mice showed specific targeting of a subcutaneous tumor; there was redistribution of the (225)Ac daughter nuclides mainly from blood to kidneys and to small intestine.
  • Therapeutic efficacy of intrathecal (225)Ac-3F8 was studied in a nude rat xenograft model of meningeal carcinomatosis.
  • The (225)Ac-3F8 treatment improved survival 2-fold from 16 to 34 days (P = 0.01).
  • In conclusion, in vivo alpha generators targeted by 3F8 warrant additional study as a possible new approach to the treatment of carcinomatous meningitis.
  • [MeSH-major] Actinium / therapeutic use. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / therapeutic use. Carcinoma / drug therapy. Carcinoma / pathology. Gangliosides / metabolism. Immunoglobulin G / immunology. Immunoglobulin G / therapeutic use. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / pathology. Neuroblastoma / drug therapy. Neuroblastoma / pathology
  • [MeSH-minor] Animals. Haplorhini. Humans. Immunoconjugates. Injections, Spinal. Mice. Rats. Rats, Nude. Survival Analysis. Tissue Distribution. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15501978.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / PHS HHS / / P01 33049; United States / PHS HHS / / R01 55349
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 3F8 antibody; 0 / Antibodies, Monoclonal; 0 / Gangliosides; 0 / Immunoconjugates; 0 / Immunoglobulin G; 65988-71-8 / ganglioside, GD2; NIK1K0956U / Actinium
  •  go-up   go-down


2. Roques B, Pichon A, De Laroche G, Garnier JF, Jacquin JP: [Intra-abdominal desmoplastic small round-cell tumors. An entity among peritoneal carcinomatoses in young adults]. Gastroenterol Clin Biol; 2000 Mar;24(3):359-60
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intra-abdominal desmoplastic small round-cell tumors. An entity among peritoneal carcinomatoses in young adults].
  • [Transliterated title] Tumeurs desmoplastiques intra-abdominales à petites cellules rondes. Une entité parmi les carcinoses péritonéales de l'adulte jeune.
  • Desmoplastic small round-cell tumors in young adults were first described in 1989.
  • They may be revealed by an abdominal mass or a peritoneal carcinomatosis.
  • The diagnosis and the initial treatment are based on debulking surgery.
  • Chemotherapy using doxorubicin, ifosfamide, etoposide and cisplatin can then be proposed.
  • [MeSH-major] Abdominal Neoplasms / diagnosis. Abdominal Neoplasms / surgery. Carcinoma / diagnosis. Carcinoma / surgery. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / surgery
  • [MeSH-minor] Abdominal Pain / etiology. Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Treatment Outcome

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10804346.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] FRANCE
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


3. Juan Vidal O, de Paz Arias L, Catalá Barceló J, García Escrig M: [Meningeal carcinomatosis as first manifestation of carcinoma of the bladder: report of 2 cases]. An Med Interna; 2000 Aug;17(8):425-8
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Meningeal carcinomatosis as first manifestation of carcinoma of the bladder: report of 2 cases].
  • [Transliterated title] Carcinomatosis meníngea como primera manifestación del carcinoma de vejiga: a propósito de dos casos.
  • Meningeal carcinomatosis may occur in 0.8-8% of patients with solid tumors.
  • The most common tumors associated with that condition are breast and small cell lung cancer.
  • Meningeal carcinomatosis from urothelial cancer is rare, and it appears described in advanced stages of disease, generally, after chemotherapy.
  • Two cases of meningeal carcinomatosis as the first manifestation of bladder cancer were reported.
  • In the second case, a 68-year-old man was admitted to our hospital with a history compatible with panhypopituitarism and pulmonary lymphangitic carcinomatosis from cancer of unknown primary site.
  • Follow-up revealed a transitional cell carcinoma of the bladder and hydrocephalus due to cerebrospinal fluid outflow obstruction.
  • We emphasize in the polymorphic presentation of meningeal carcinomatosis and the necessity to consider the bladder as primary tumor localization.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Transitional Cell / secondary. Meningeal Neoplasms / secondary. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11218991.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


Advertisement
4. Chen YM, Chen MC, Tsai CM, Perng RP: Intrathecal gemcitabine chemotherapy for non-small cell lung cancer patients with meningeal carcinomatosis--a case report. Lung Cancer; 2003 Apr;40(1):99-101
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrathecal gemcitabine chemotherapy for non-small cell lung cancer patients with meningeal carcinomatosis--a case report.
  • Intrathecal chemotherapy has been the mainstay treatment for meningeal carcinomatosis for decades.
  • However, this has not been the case with non-small cell lung cancer (NSCLC), due to the low efficacy of the drugs that could be used before.
  • Gemcitabine is an effective drug against NSCLC and has a structure similar to cytarabine, which has been widely used in intrathecal chemotherapy.
  • Thus, intrathecal gemcitabine chemotherapy might prove to be suitable for leptomeningeal carcinomatosis induced by NSCLC.
  • We herein report our experience using gemcitabine intrathecal injections in a NSCLC patient with leptomeningeal carcinomatosis.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Lung Neoplasms / drug therapy. Meningeal Neoplasms / drug therapy
  • [MeSH-minor] Humans. Injections, Spinal. Magnetic Resonance Imaging. Male. Middle Aged. Ribonucleotide Reductases / antagonists & inhibitors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12660014.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 1.17.4.- / Ribonucleotide Reductases
  •  go-up   go-down


5. Msika S, Gruden E, Sarnacki S, Orbach D, Philippe-Chomette P, Castel B, Sabaté JM, Flamant Y, Kianmanesh R: Cytoreductive surgery associated to hyperthermic intraperitoneal chemoperfusion for desmoplastic round small cell tumor with peritoneal carcinomatosis in young patients. J Pediatr Surg; 2010 Aug;45(8):1617-21
Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery associated to hyperthermic intraperitoneal chemoperfusion for desmoplastic round small cell tumor with peritoneal carcinomatosis in young patients.
  • PURPOSE: Desmoplastic round small cell tumor (DRSCT) is a rare intraabdominal mesenchymal tissue neoplasm in young patients and spreads through the abdominal cavity.
  • Its prognosis is poor despite a multimodal therapy including chemotherapy, radiotherapy, and surgical cytoreduction (CS).
  • hyperthermic intraperitoneal chemotherapy (HIPEC) is considered as an additional strategy in the treatment of peritoneal carcinomatosis; for this reason, we planned to treat selected cases of children with DRSCT using CS and HIPEC.
  • There was no other complication related to HIPEC procedure.
  • CONCLUSIONS: Surgical cytoreduction and HIPEC provide a local alternative approach to systemic chemotherapy in the control of microscopic peritoneal disease in DRSCT, with an acceptable morbidity, and may be considered as a potential beneficial adjuvant waiting for a more specific targeted therapy against the fusion protein.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / surgery. Chemotherapy, Cancer, Regional Perfusion / methods. Hyperthermia, Induced / methods. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adolescent. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / surgery. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Injections, Intraperitoneal. Male. Palliative Care. Peritoneum / pathology. Peritoneum / surgery. Treatment Outcome. Tumor Burden / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20713209.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Kim DY, Lee KW, Yun T, Park SR, Jung JY, Kim DW, Kim TY, Heo DS, Bang YJ, Kim NK: Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn J Clin Oncol; 2003 Dec;33(12):608-12
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone.
  • OBJECTIVE: To compare the efficacy of intrathecal methotrexate single therapy with three-drug combination therapy in patients with leptomeningeal carcinomatosis.
  • METHODS: Fifty-five patients who had pathologically proven leptomeningeal carcinomatosis of a solid tumor were evaluated in terms of pathological response.
  • The cytological response rate to intrathecal chemotherapy was significantly higher in the MHA group than in the M group (38.5 vs 13.8%, P = 0.036).
  • CONCLUSION: Combination intrathecal chemotherapy with methotrexate, cytosine arabinoside and hydrocortisone showed more favorable effects than methotrexate single therapy for leptomeningeal carcinomatosis in solid tumors.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Meningeal Neoplasms / drug therapy. Methotrexate / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / mortality. Carcinoma, Small Cell / pathology. Cytarabine / administration & dosage. Drug Administration Schedule. Female. Humans. Hydrocortisone / administration & dosage. Injections, Spinal. Male. Middle Aged. Retrospective Studies. Survival Rate

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14769837.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


7. Abe T, Hayashi M, Tsutsui N, Ito K, Haraguchi M: [Two cases of meningeal carcinomatosis during gefitinib therapy for non-small cell lung cancer]. Nihon Kokyuki Gakkai Zasshi; 2006 Feb;44(2):144-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of meningeal carcinomatosis during gefitinib therapy for non-small cell lung cancer].
  • "Case 1" A 56-year-old woman who suffered from postoperative recurrent non-small cell lung cancer received gefitinib therapy.
  • Approximately 7 months after the therapy was begun, although the intrathoracic disease responded to the treatment, she developed meningeal carcinomatosis and died of rapidly progressive central nervous system disease.
  • "Case 2" A 46-year-old man with stage IV non-small cell lung cancer started gefitinib therapy after chemotherapy.
  • The pulmonary lesions markedly improved responding to gefitinib therapy, however, approximately 6 months after the therapy was begun, multiple brain metastasis and meningeal carcinomatosis were detected.
  • Approximately 4 months after the diagnosis of meningeal carcinomatosis, he died of disease progression and disturbance of consciousness.
  • It has been reported that the central nervous system is a frequent metastatic site of non-small cell lung cancer in patients treated with gefitinib.
  • We report two cases of meningeal carcinomatosis that occurred during the period in which their intrathoracic disease was responding to gefitinib therapy.
  • We should consider the possibility of metastatic central nervous system disease, even in patients in whom gefitinib therapy is apparently successful.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / etiology. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Meningeal Neoplasms / etiology. Quinazolines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Disease Progression. Fatal Outcome. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17228810.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


8. Yamada T, Ohtsubo K, Mouri H, Yamashita K, Yasumoto K, Izumi K, Zen Y, Watanabe H, Yano S: Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis. Int J Clin Oncol; 2009 Oct;14(5):468-72
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis.
  • We report the case of a 65-year-old man with recurrent prostate cancer who presented with meningeal carcinomatosis.
  • In September 2007, he had been diagnosed with mixed type small cell carcinoma and adenocarcinoma at clinical stage T4N1M1 (primary prostate tumor with multiple bone, liver, and lymph node metastases) and hormonal therapy had been administered.
  • Following an increase in the level of pro-gastrin-releasing peptide (ProGRP), combined chemotherapy with cisplatin plus etoposide was implemented and showed efficacy in targeting the small cell carcinoma.
  • Small cell carcinoma of the prostate complicated with meningeal carcinomatosis was diagnosed.
  • A different chemotherapy regimen was then administered, consisting of a combination of carboplatin plus irinotecan, which is one of the most common first-line treatments for extensive-stage small cell lung carcinoma.
  • From day 20 after the initiation of this therapy, he gradually recovered from the signs of meningeal irritation, and brain MRI showed nearly normal findings; also, the serum level of ProGRP was reduced.
  • In conclusion, we report the efficacy of combined treatment with carboplatin plus irinotecan for small cell carcinoma of the prostate complicated with meningeal carcinomatosis.
  • Because this clinical condition is extremely rare, a gold standard treatment has yet to be established.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Meningeal Carcinomatosis / drug therapy. Neoplasm Recurrence, Local. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Carboplatin / administration & dosage. Humans. Magnetic Resonance Imaging. Male. Peptide Fragments / blood. Recombinant Proteins / blood. Spinal Puncture. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2002 Sep;37(3):319-23 [12234702.001]
  • [Cites] J Urol. 1992 Mar;147(3 Pt 2):804-7 [1311395.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3072-80 [12118020.001]
  • [Cites] Lung Cancer. 2003 Jun;40(3):333-8 [12781433.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):2122-6 [11391593.001]
  • [Cites] Neuro Oncol. 2009 Feb;11(1):80-91 [18784279.001]
  • [Cites] Br J Cancer. 2007 Jul 16;97(2):162-9 [17579629.001]
  • [Cites] Int J Urol. 2006 Sep;13(9):1254-8 [16984566.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3281-4 [18591564.001]
  • [Cites] Urology. 1992 May;39(5):411-6 [1315995.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):85-91 [11784874.001]
  • [Cites] Cancer. 1984 Jun 15;53(12):2728-30 [6722732.001]
  • [Cites] Urol Oncol. 2006 Jul-Aug;24(4):313-7 [16818183.001]
  • [Cites] J Urol. 1992 Mar;147(3 Pt 2):935-7 [1311396.001]
  • [Cites] J Clin Oncol. 1986 Nov;4(11):1620-7 [3021922.001]
  • [Cites] Mol Interv. 2003 Mar;3(2):90-105, 51 [14993430.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1168-71 [18309954.001]
  • [Cites] Lung Cancer. 2006 Dec;54(3):365-70 [17011068.001]
  • [Cites] Int J Clin Oncol. 2008 Apr;13(2):169-72 [18463964.001]
  • [Cites] Biol Pharm Bull. 1999 Apr;22(4):428-31 [10328568.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):733-9 [9477107.001]
  • [Cites] Clin Lung Cancer. 2008 Jan;9(1):35-8 [18282356.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9209-16 [15604294.001]
  • (PMID = 19856060.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Peptide Fragments; 0 / Recombinant Proteins; 0 / pro-gastrin-releasing peptide (31-98); 0H43101T0J / irinotecan; BG3F62OND5 / Carboplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


11. Mourgela S, Sakellaropoulos A, Ardavanis A: Leptomeningeal carcinomatosis presenting as bilateral sensorineural deafness and unilateral facial palsy. J BUON; 2009 Apr-Jun;14(2):317-9
Genetic Alliance. consumer health - Deafness.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal carcinomatosis presenting as bilateral sensorineural deafness and unilateral facial palsy.
  • This paper describes the case of a 56-year-old man with a history of small cell lung cancer under chemotherapy, who presented with left-sided peripheral facial palsy and progressive bilateral sensorineural deafness due to leptomeningeal carcinomatosis (LMC).
  • Whole brain radiation therapy and methotrexate intrathecally were applied to the patient.
  • [MeSH-major] Facial Paralysis / etiology. Hearing Loss, Sensorineural / etiology. Meningeal Carcinomatosis / complications. Small Cell Lung Carcinoma / complications
  • [MeSH-minor] Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19650186.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


12. Hermann B, Hültenschmidt B, Sautter-Bihl ML: Radiotherapy of the neuroaxis for palliative treatment of leptomeningeal carcinomatosis. Strahlenther Onkol; 2001 Apr;177(4):195-9
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy of the neuroaxis for palliative treatment of leptomeningeal carcinomatosis.
  • BACKGROUND: Leptomeningeal carcinomatosis occurs in about 5% of solid tumors and may seriously compromise quality of life.
  • Aim of the present study was to evaluate the feasibility of craniospinal irradiation with and without intrathecal chemotherapy and its efficacy with regard to symptom palliation and survival.
  • PATIENTS AND METHODS: 16 patients (mean age 46 years; nine breast cancers, five lung cancers, one renal cell cancer, one tumor of unknown primary site) with leptomeningeal carcinomatosis occurring after a median interval from primary tumor diagnosis of 5 months (0-300 months) received craniospinal irradiation between October 1995 and May 2000.
  • The median total dose was 36 Gy (à 1.6-2.0 Gy).
  • RESULTS: Median survival was 12 weeks, 8 weeks after radiotherapy alone, 16 weeks after combined modality treatment.
  • CONCLUSION: Craniospinal radiotherapy is feasible and effective for palliative treatment of leptomeningeal carcinomatosis.
  • As far as the small patient number permits any definite conclusions, combined modality treatment seems superior to irradiation alone.
  • [MeSH-major] Brain / drug effects. Carcinoma / radiotherapy. Meningeal Neoplasms / radiotherapy. Palliative Care / methods. Spine / drug effects
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Feasibility Studies. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11370554.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Popiolek DA, Kumar AR, Mittal K: Large cell variant of small cell carcinoma, hypercalcemic type, of primary peritoneal origin. Gynecol Oncol; 2005 Jan;96(1):249-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large cell variant of small cell carcinoma, hypercalcemic type, of primary peritoneal origin.
  • BACKGROUND: Large cell variant of small cell carcinoma hypercalcemic type (SCC-HT) is extremely rare.
  • Intraoperative impression of peritoneal carcinomatosis was confirmed on frozen section.
  • The tumor had features of large cell variant of SCC-HT, described in the ovary.
  • The patient received standard chemotherapy for SCC.
  • CONCLUSION: SCC-HT should be considered in the differential diagnosis of primary neoplasms of the peritoneum.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Hypercalcemia / pathology. Peritoneal Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15589611.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Cohen Y, Amir G, Polliack A: Development and rapid dissemination of Merkel-cell carcinomatosis following therapy with fludarabine and rituximab for relapsing follicular lymphoma. Eur J Haematol; 2002 Feb;68(2):117-9
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development and rapid dissemination of Merkel-cell carcinomatosis following therapy with fludarabine and rituximab for relapsing follicular lymphoma.
  • This report deals with an unusual case of a patient with follicular small cleaved lymphocytic lymphoma who developed Merkel-cell carcinoma soon after receiving chemoimmunotherapy with a fludarabine-containing regimen and rituximab.
  • The presentation of the Merkel-cell carcinoma in this patient was atypical because of the absence of dermal involvement and the very rapid clinical progression.
  • In the light of recent reports which suggest a possible link between the immunocompromised state and the development of Merkel-cell carcinoma, the atypical presentation seen in this patient may indeed imply a possible link between the therapy given and the development of Merkel-cell carcinoma.
  • To the best of our knowledge, this is the first documentation of Merkel-cell carcinoma appearing in a patient soon after treatment with fludarabine and/or rituximab.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antineoplastic Agents / adverse effects. Carcinoma, Merkel Cell / etiology. Lymphoma, Follicular / drug therapy. Vidarabine / adverse effects
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Humans. Male. Middle Aged. Neoplasms, Second Primary / etiology. Neoplasms, Second Primary / pathology. Recurrence. Rituximab. Salvage Therapy

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12061321.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


15. Colombo PE, Boustta M, Poujol S, Pinguet F, Rouanet P, Bressolle F, Vert M: Biodistribution of doxorubicin-alkylated poly(L-lysine citramide imide) conjugates in an experimental model of peritoneal carcinomatosis after intraperitoneal administration. Eur J Pharm Sci; 2007 May;31(1):43-52
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biodistribution of doxorubicin-alkylated poly(L-lysine citramide imide) conjugates in an experimental model of peritoneal carcinomatosis after intraperitoneal administration.
  • Intraperitoneal (i.p.) chemotherapy after cytoreductive surgery is associated with high systemic or local toxicity.
  • A macromolecular drug delivery system was evaluated with the aim of improving the therapeutic index of i.p. chemotherapy.
  • Peritoneal carcinomatosis was generated in BDIX rats (n=55) by i.p. injection of 2 million DHDK12 cells.
  • Fourteen days later, doxorubicin (DOX) and two DOX-alkylated poly(L-lysine citramide imide) conjugates bearing 9.5% and 20.5% (w/w) chemically bound drug, respectively, were given i.p. to rats at a single 2 mg DOX/kg dose.
  • Free and polymer-bound DOX were assessed in plasma, peritoneal fluid, abdominal tissues and heart, 15 min, 2, 6, 24, 48 and 168 h after injection.
  • According to pharmacokinetic profiles, the peritoneal fluid areas under the concentration versus time curves (AUCs) were 2 and 2.6 times greater for the conjugates (P-DOX20 and P-DOX10, respectively) than for the free drug, respectively.
  • Conjugates crossed the peritoneal barrier slower than the free drug.
  • For the tumor, AUCs were, respectively, 3 and 7 times higher for the conjugates than for free DOX.
  • The elimination half-lives of the conjugates were higher than that calculated for the free drug.
  • Only very small concentrations were detected in peripheral organs and in the heart.
  • In conclusion, the conjugates have higher elimination half-lives than free DOX and were preferentially retained in abdominal organs and in the peritoneal carcinomatosis.
  • [MeSH-major] Carcinoma / metabolism. Doxorubicin / pharmacokinetics. Nylons / chemistry. Peritoneal Neoplasms / metabolism
  • [MeSH-minor] Animals. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / adverse effects. Antibiotics, Antineoplastic / pharmacokinetics. Area Under Curve. Ascitic Fluid / chemistry. Cell Line, Tumor. Male. Molecular Structure. Neoplasms, Experimental / drug therapy. Neoplasms, Experimental / metabolism. Neoplasms, Experimental / pathology. Peritonitis / chemically induced. Rats. Rats, Inbred Strains

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17383164.001).
  • [ISSN] 0928-0987
  • [Journal-full-title] European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • [ISO-abbreviation] Eur J Pharm Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Nylons; 0 / poly(lysine citramide imide); 80168379AG / Doxorubicin
  •  go-up   go-down


16. Mingo L, Seguel F, Rollán V: Intraabdominal desmoplastic small round cell tumour. Pediatr Surg Int; 2005 Apr;21(4):279-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraabdominal desmoplastic small round cell tumour.
  • Desmoplastic small round cell tumour (DSRCT) is an extremely rare neoplasm.
  • He was treated with chemotherapy but died of hepatic failure.
  • After treatment with chemotherapy, two operations were carried out to resect different intraabdominal masses.
  • The patient died with peritoneal carcinomatosis 2 months after the last operation.
  • The first patient died due to the advanced stage of the disease, and the second died after chemotherapy, peripheral blood stem transplantation, and multiple operations.
  • The occurrence of this type of tumour in the paediatric age group as well as its high malignancy is noteworthy.
  • Until more effective forms of treatment are found, we recommend treatment with chemotherapy, surgery, and radiotherapy, with close monitoring of the patient.
  • [MeSH-major] Abdominal Neoplasms / surgery. Carcinoma, Small Cell / surgery
  • [MeSH-minor] Child. Child, Preschool. Fatal Outcome. Humans. Inguinal Canal. Liver Neoplasms / diagnostic imaging. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Nov;22(11):1303-13 [9808123.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):845-51 [8756380.001]
  • [Cites] Eur J Pediatr Surg. 2002 Oct;12(5):333-6 [12469262.001]
  • [Cites] J Surg Oncol. 1999 Aug;71(4):269-72 [10440769.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 Sep-Oct;22(5):446-50 [11037858.001]
  • [Cites] Pediatr Hematol Oncol. 1996 Jan-Feb;13(1):95-9 [8718507.001]
  • [Cites] Ann Surg Oncol. 1998 Jul-Aug;5(5):416-22 [9718171.001]
  • [Cites] Pediatr Pathol. 1989;9(2):177-83 [2473463.001]
  • [Cites] Surg Oncol. 2000 Aug;9(2):77-81 [11094327.001]
  • (PMID = 15761710.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Terada T: KIT-positive primary small cell carcinoma of the endometrium: a case report with immunohistochemical and molecular genetic analysis of KIT and PDGFRA genes. Arch Gynecol Obstet; 2010 Oct;282(4):413-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KIT-positive primary small cell carcinoma of the endometrium: a case report with immunohistochemical and molecular genetic analysis of KIT and PDGFRA genes.
  • BACKGROUND: Primary small cell carcinoma of the endometrium is very rare, and there have been no reports on KIT and PDGFRA in endometrial small cell carcinoma.
  • Endometrial cytology and biopsy revealed small cell carcinoma.
  • Scrutiny of the body showed stage III endometrial carcinoma with metastases.
  • The patient received chemotherapy and radiation, but showed a downhill course, and died of carcinomatosis 6 months after the initial presentation.
  • CONCLUSION: The present case is the first reported case of primary small cell carcinoma of the endometrium with an examination of KIT and PDGFRA expressions and KIT and PDFGRA gene mutations.
  • [MeSH-major] Carcinoma, Small Cell / genetics. Endometrial Neoplasms / genetics. Proto-Oncogene Proteins c-kit / genetics. Receptor, Platelet-Derived Growth Factor alpha / genetics
  • [MeSH-minor] Aged, 80 and over. Biopsy. DNA Mutational Analysis. Drug Therapy. Fatal Outcome. Female. Humans. Immunohistochemistry. Polymerase Chain Reaction. Radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20035340.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


18. Sendler A, Strumberg D, Tannapfel A: [Carcinoma of unknown primary site (CUP syndrome)]. Chirurg; 2008 Jul;79(7):689-95; quiz 696
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Carcinoma of unknown primary site (CUP syndrome)].
  • Despite the growing array of sophisticated diagnostic tools for establishing a diagnosis of human neoplasia, 2-6% of all cancer patients still present metastatic cancer of which detailed investigations fail to identify the primary anatomic site.
  • At the time of first diagnosis with carcinoma of unknown primary site, usually more than 80% of patients present with dissemination.
  • Objective long-term response is possible in combination with chemotherapy in patients with small-cell malignancies, peritoneal carcinomatosis (in women), or poorly differentiated carcinomas involving external lymph nodes, mediastinum, or retroperitoneum but without metastases to viscera or bone.
  • Toxic therapies are recommended only for palliation of symptoms and maintaining quality of life support in patients with good functional status.
  • Patients should be encouraged to participate in clinical trials for novel therapies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasms, Unknown Primary / drug therapy
  • [MeSH-minor] Diagnosis, Differential. Follow-Up Studies. Humans. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Biother Radiopharm. 2003 Feb;18(1):47-58 [12667308.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):2094-103 [7636553.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Feb;41(2):205-11 [11856596.001]
  • [Cites] Pathologe. 2002 May;23(3):183-97 [12089786.001]
  • [Cites] Ann Surg Oncol. 2001 Jun;8(5):425-31 [11407517.001]
  • [Cites] Onkologie. 2001 Feb;24(1):38-43 [11441279.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1937-44 [15128893.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4679-83 [12488413.001]
  • [Cites] Ann Oncol. 2001 Nov;12 (11):1605-9 [11822762.001]
  • [Cites] Eur J Surg Oncol. 2002 Mar;28(2):147-52 [11884050.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3101-7 [10963638.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3611-3 [12552964.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1945-52 [15128894.001]
  • [Cites] Ann Oncol. 2003 Aug;14(8):1306-11 [12881397.001]
  • [Cites] Clin Radiol. 2002 Dec;57(12):1073-7 [12475531.001]
  • [Cites] Med Sci Monit. 2002 Feb;8(2):MT25-30 [11859288.001]
  • [Cites] Urologe A. 2006 May;45(5):614-9 [16710679.001]
  • (PMID = 18584137.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


19. Hashimoto N, Imaizumi K, Honda T, Kawabe T, Nagasaka T, Shimokata K, Hasegawa Y: Successful re-treatment with gefitinib for carcinomatous meningitis as disease recurrence of non-small-cell lung cancer. Lung Cancer; 2006 Sep;53(3):387-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful re-treatment with gefitinib for carcinomatous meningitis as disease recurrence of non-small-cell lung cancer.
  • The good response to gefitinib treatment was supported in part by the existence of epidermal growth factor receptor mutation in carcinoma cells in the specimen obtained from transbronchial lung biopsy, in which E709G in exon 18 and L858R in exon 21 were shown.
  • Although carcinomatous meningitis had been well controlled by the treatment with gefitinib, serum carcinoembryonic antigen (CEA) level increased with re-growth of primary tumor and development of lymphangitic carcinomatosis.
  • Immunohistochemical findings revealed de novo emergence of CEA-producing carcinoma cells in the biopsy specimen taken after recurrence of pulmonary lesion during re-treatment of gefitinib, but revealed little or no CEA expression in the specimen obtained at first presentation.
  • These facts may suggest the possibility of oligo clonality of carcinoma cells in this case.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / pharmacology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Aged. Biopsy. Carcinoembryonic Antigen / metabolism. Exons. Female. Humans. Magnetic Resonance Imaging / methods. Mutation. Receptor, Epidermal Growth Factor / genetics. Recurrence

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16824645.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carcinoembryonic Antigen; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


20. Tentes AA, Mirelis CG, Markakidis SK, Bekiaridou KA, Bougioukas IG, Xanthoulis AI, Tsalkidou EG, Zafiropoulos GH, Nikas IH: Long-term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):490-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures.
  • The impact of cytoreductive surgery with standard peritonectomy procedures has not been extensively assessed in the treatment of advanced ovarian cancer.
  • Complete cytoreductive surgery, small-volume tumor, low-grade tumor, the absence of distant metastases, the use of systemic adjuvant chemotherapy, performance status >70%, and limited extent of peritoneal carcinomatosis were favorable indicators of survival.
  • Complete cytoreduction (P= 0.000) and treatment with systemic chemotherapy (P= 0.001) independently influenced survival.
  • Cytoreductive surgery with standard peritonectomy procedures followed by adjuvant chemotherapy offers long-term survival in women with advanced ovarian cancer who have limited peritoneal carcinomatosis and no distant and irresectable metastases.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / mortality. Carcinoma, Papillary / surgery. Chemotherapy, Adjuvant. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / surgery. Female. Hospital Mortality. Humans. Lymphatic Metastasis / pathology. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Postoperative Complications / etiology. Postoperative Complications / mortality. Prognosis. Retrospective Studies. Survival Rate. Survivors. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681716.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Choong NW, Dietrich S, Seiwert TY, Tretiakova MS, Nallasura V, Davies GC, Lipkowitz S, Husain AN, Salgia R, Ma PC: Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. Nat Clin Pract Oncol; 2006 Jan;3(1):50-7; quiz 1 p following 57
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A 70-year-old Japanese-American woman who had never smoked was diagnosed with stage IV non-small-cell lung cancer with rib metastases.
  • While receiving treatment with erlotinib, an epidermal growth factor receptor small-molecule inhibitor, she progressed and developed new brain metastases.
  • She failed further chemotherapy treatments and subsequently developed extensive symptomatic leptomeningeal carcinomatosis associated with diplopia, hemiparesis, weight loss, and incontinence.
  • DIAGNOSIS: Erlotinib-refractory stage IV lung adenocarcinoma and end-stage symptomatic leptomeningeal metastases with a novel double L858R + E884K somatic mutation of the EGFR.
  • [MeSH-major] Adenocarcinoma / pathology. Bone Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / pathology. Meningeal Neoplasms / secondary. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / genetics. Ribs / pathology
  • [MeSH-minor] Aged. Erlotinib Hydrochloride. Female. Humans. Mutation. Treatment Failure

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16407879.001).
  • [ISSN] 1743-4254
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


22. Seeber S, Strumberg D: [Metastases with CUP syndrome]. Urologe A; 2006 May;45(5):614-9
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Metastasen mit unbekanntem Primärtumor (CUP).
  • Carcinoma of unknown primary is common, accounting for 2-6% of all cancer patients.
  • At the time point of first diagnosis of CUP syndrome, usually more than 80% of the patients present a disseminated situation.
  • In patients with small cell malignancies, peritoneal carcinomatosis (in women), poorly differentiated carcinomas involving external lymph nodes, mediastinum, or retroperitoneum, but without metastases to viscera or bone, objective long-term responses are possible with combination chemotherapy.
  • For all other patients, toxic therapies are recommended only for patients with good functional status, for palliation of symptoms when they develop, and for continuous support of the quality of life.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Unknown Primary / diagnosis. Neoplasms, Unknown Primary / drug therapy. Palliative Care / methods. Urogenital Neoplasms / drug therapy. Urogenital Neoplasms / secondary
  • [MeSH-minor] Clinical Trials as Topic. Humans. Neoplasm Recurrence, Local / prevention & control. Practice Guidelines as Topic. Practice Patterns, Physicians'. Quality of Life. Syndrome. Terminal Care / methods

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1986 Jan 1;57(1):120-4 [3940611.001]
  • [Cites] Cancer Biother Radiopharm. 2003 Feb;18(1):47-58 [12667308.001]
  • [Cites] Arch Surg. 1990 Feb;125(2):210-4 [2302061.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):2094-103 [7636553.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Feb;41(2):205-11 [11856596.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1720-5 [7541451.001]
  • [Cites] Pathologe. 2002 May;23(3):183-97 [12089786.001]
  • [Cites] Ann Surg Oncol. 2001 Jun;8(5):425-31 [11407517.001]
  • [Cites] Arch Intern Med. 1988 Sep;148(9):2035-9 [3046543.001]
  • [Cites] J Clin Oncol. 1992 Jun;10(6):912-22 [1375284.001]
  • [Cites] Anticancer Res. 1993 Sep-Oct;13(5A):1619-23 [8239543.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):191-6 [12562643.001]
  • [Cites] Semin Diagn Pathol. 2000 Aug;17(3):184-93 [10968704.001]
  • [Cites] Semin Oncol. 1993 Jun;20(3):206-28 [8503017.001]
  • [Cites] Cancer Res. 1989 Aug 1;49(15):4311-5 [2743318.001]
  • [Cites] Oncogene. 2004 Jun 24;23(29):5092-4 [15107816.001]
  • [Cites] Onkologie. 2001 Feb;24(1):38-43 [11441279.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1937-44 [15128893.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4679-83 [12488413.001]
  • [Cites] Bull Cancer. 2001 Jun;88(6):619-27 [11459709.001]
  • [Cites] Cancer. 1998 Mar 15;82(6):1160-6 [9506364.001]
  • [Cites] J Nucl Med. 2000 May;41(5):816-22 [10809197.001]
  • [Cites] J Pathol. 2001 Sep;195(1):41-52 [11568890.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):143-7 [10758316.001]
  • [Cites] Ann Oncol. 2001 Nov;12 (11):1605-9 [11822762.001]
  • [Cites] Ugeskr Laeger. 2001 Mar 5;163(10):1432-6 [11257752.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1272-80 [8201389.001]
  • [Cites] Semin Oncol. 1993 Jun;20(3):273-8 [8503023.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2056-66 [9164218.001]
  • [Cites] Eur J Surg Oncol. 2002 Mar;28(2):147-52 [11884050.001]
  • [Cites] J Biochem Mol Biol. 2003 Jan 31;36(1):43-8 [12542974.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3101-7 [10963638.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3403-10 [10589751.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3611-3 [12552964.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1945-52 [15128894.001]
  • [Cites] Ann Oncol. 2003 Aug;14(8):1306-11 [12881397.001]
  • [Cites] Wien Klin Wochenschr. 1989 Jul 14;101(14):464-72 [2672606.001]
  • [Cites] Clin Radiol. 2002 Dec;57(12):1073-7 [12475531.001]
  • [Cites] Laryngoscope. 1987 Sep;97(9):1080-4 [3626734.001]
  • [Cites] Med Sci Monit. 2002 Feb;8(2):MT25-30 [11859288.001]
  • (PMID = 16710679.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 40
  •  go-up   go-down


23. Barabas K, Milner R, Lurie D, Adin C: Cisplatin: a review of toxicities and therapeutic applications. Vet Comp Oncol; 2008 Mar;6(1):1-18
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin: a review of toxicities and therapeutic applications.
  • Unfortunately, the mechanism for cisplatin nephrotoxicity has not been completely elucidated; however, many theories have been developed.
  • Cisplatin has shown activity against osteosarcoma, transitional cell carcinoma, squamous cell carcinoma (SCC), melanoma, mesothelioma, carcinomatosis and germinal cell tumours in the dog.
  • Intralesional cisplatin has been utilized in horses for the treatment of SCC and sarcoids.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Cisplatin / adverse effects. Cisplatin / therapeutic use. Kidney Diseases / veterinary. Neoplasms / veterinary
  • [MeSH-minor] Animals. Dog Diseases / drug therapy. Dogs. Horse Diseases / drug therapy. Horses


24. Edgerton CC, Gilman M, Roth BJ: Topotecan-induced bronchiolitis. South Med J; 2004 Jul;97(7):699-701
Hazardous Substances Data Bank. Topotecan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Topotecan HCl is an antitumor drug exhibiting topoisomerase 1-inhibitory activity.
  • Topotecan is used in the treatment of metastatic carcinoma of the ovary and as second-line treatment of small-cell lung cancer.
  • The authors describe the development of obliterative bronchiolitis, as evidenced by radiographic and pulmonary function testing abnormalities, in a 61-year-old woman who presented with dyspnea, and who was receiving topotecan for peritoneal carcinomatosis.
  • [MeSH-minor] Carcinoma / drug therapy. Female. Humans. Middle Aged. Peritoneal Neoplasms / drug therapy. Topotecan / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15301130.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Topoisomerase I Inhibitors; 7M7YKX2N15 / Topotecan
  •  go-up   go-down


25. Choi YW, Munden RF, Erasmus JJ, Park KJ, Chung WK, Jeon SC, Park CK: Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis. Radiographics; 2004 Jul-Aug;24(4):985-97; discussion 998
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis.
  • Radiation-induced lung disease (RILD) due to radiation therapy is common.
  • Radiologic manifestations are usually confined to the lung tissue within the radiation port and are dependent on the interval after completion of treatment.
  • However, the use of oblique beam angles and the development of newer irradiation techniques such as three-dimensional conformal radiation therapy can result in an unusual distribution of these findings.
  • Awareness of the atypical manifestations of RILD can be useful in preventing confusion with infection, recurrent malignancy, lymphangitic carcinomatosis, and radiation-induced tumors.
  • In addition, knowledge of radiologic findings that are outside the expected pattern for RILD can be useful in diagnosis of infection or recurrent malignancy.
  • A comprehensive understanding of the full spectrum of these manifestations is important to facilitate diagnosis and management in cancer patients treated with radiation therapy.
  • [MeSH-minor] Adenocarcinoma / radiography. Adenocarcinoma / radiotherapy. Adult. Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / pharmacology. Breast Neoplasms / radiotherapy. Bronchiectasis / etiology. Bronchiectasis / radiography. Carcinoma, Non-Small-Cell Lung / radiography. Carcinoma, Non-Small-Cell Lung / radiotherapy. Diagnosis, Differential. Disease Progression. Dose Fractionation. Esophageal Neoplasms / radiotherapy. Female. Hodgkin Disease / radiotherapy. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / radiotherapy. Male. Middle Aged. Neoplasm Recurrence, Local / radiography. Neoplasms, Radiation-Induced / diagnosis. Radiation Tolerance / drug effects. Radiotherapy Dosage. Radiotherapy, Conformal / adverse effects

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright RSNA, 2004
  • (PMID = 15256622.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 59
  •  go-up   go-down


26. Torrejón Reyes PN, Frisancho O, Gómez A, Yábar A: [Malignant peritoneal mesothelioma]. Rev Gastroenterol Peru; 2010 Jan-Mar;30(1):82-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The peritoneal mesothelioma is a rare pathology with unspecific symptoms reason to be a difficult diagnosis.
  • We report a case of a 58 year old man with diabetes mellitus type 2, arterial hypertension and smoking; without precedent of asbestos exposure.
  • Cytology: mesothelial cells with changes of type reagent, Block cell for tumour cells: negative.
  • Colonoscopy: two small sessile polyps in sigmoid colon.
  • The finds of the laparoscopy were interpreted like carcinomatosis or peritoneal tuberculosis.
  • The report of the peritoneal biopsy was informed as suggestive of undifferentiated carcinoma; the reappraisal with inmunohystochemic (calretinin +,cytokeratin +, vimentin +) indicated malignant peritoneal mesothelioma, type epithelial.
  • The patient was transferred to the Service of Oncology where they initiated chemotherapy with Cysplatin (CDDP) and died 20 days later.
  • The malignant mesothelioma peritoneal is a unfrequent entity, with limited therapeutic options; generally detected late, with a palliative treatment.

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20445731.001).
  • [ISSN] 1022-5129
  • [Journal-full-title] Revista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú
  • [ISO-abbreviation] Rev Gastroenterol Peru
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Peru
  •  go-up   go-down






Advertisement